News

The new facility will offer manufacturing capacity for emerging compounds within the company’s oncology and immunology pipeline to serve markets globally. Scheduled to be operational by 2019, the

US patent No. 8,642,564 provides methods for oral delivery of nucleotide-oligomer analogs including anti-sense and RNA interference drugs. Such drugs represent an important new class of therapeutics but

This patent provides for once-weekly oral administration of selective inhibitors of type 1 and/or type 2 isoforms of steroid 5a-reductase to patients with nodulocystic and conglobate acne vulgaris.

Under the deal, the company will have sole rights to develop and market the technology across the world. The company said that protecting the fundamental enabling technology establishes

The trials will be conducted under the supervision of GRU Cancer Center director and former chief of the Vaccines Section at the National Cancer Institute Dr Samir Khleif.

For the acquisition, Innate Pharma will pay €2m in cash and 600,000 shares to Novo Nordisk for licencing the anti-NKG2A antibody. In addition, Novo Nordisk may be eligible

Regulus will lead development of its fibrosis program targeting microRNA-21 (miR-21) for the treatment of Alport Syndrome, an orphan, life-threatening genetic kidney disease with no approved therapy, and

In the light of these results, Ipsen announces its intention to file the first ready-to-use liquid toxin A in Europe and in the Rest of the World (ROW).

A Phase I/II clinical trial will be carried out by Pfizer and Merck that will assess the safety and anti-cancer efficacy of MK-3475 combined with Pfizer’s small molecule